Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008;4(6):1159-66.
doi: 10.2147/vhrm.s3510.

Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine

Menno T Pruijm  1 , Marc P Maillard, Michel Burnier
Affiliations
Review

Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine

Menno T Pruijm et al. Vasc Health Risk Manag. 2008.

Abstract

Despite the development of many effective antihypertensive drugs, target blood pressures are reached in only a minority of patients in clinical practice. Poor adherence to drug therapy and the occurrence of side effects are among the main reasons commonly reported by patients and physicians to explain the poor results of actual antihypertensive therapies. The development of new effective antihypertensive agents with an improved tolerability profile might help to partly overcome these problems. Lercanidipine is an effective dihydropyridine calcium channel blocker of the third generation characterized by a long half-life and its lipophylicity. In contrast to first-generation dihydropyridines, lercanidipine does not induce reflex tachycardia and induces peripheral edema with a lower incidence. Recent data suggest that in addition to lowering blood pressure, lercanidipine might have some renal protective properties. In this review we shall discuss the problems of drug adherence in the management of hypertension with a special emphasis on lercanidipine.

Keywords: calcium antagonists; compliance; hypertension.

PubMed Disclaimer

References

    1. Acanfora D, Gheorghiade M, Trojano L, et al. A randomized, double-blind comparison of lercanidipine 10 and 20 mg in patients with stable effort angina: clinical evaluation of cardiac function by ambulatory ventricular scintigraphic monitoring. Am J Ther. 2004;11:423–32. - PubMed
    1. Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens. 2006;24:185–92. - PubMed
    1. Ambrosioni E, Leonetti G, Pessina A, Rappelli A, Trimarco B, et al. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. J Hypertens. 2000;18:1691–9. - PubMed
    1. Angelico P, Guarnieri N, Leonardi A, et al. Vascular-selective effect of leranidipine and other 1,4 dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol. 1999;51:709–14. - PubMed
    1. Arima S, Ito S, Omata K, et al. Role of actions of calcium antagonists on efferent arterioles with special references to glomerular hypertension. Am J Nephrol. 1996;23:229–44. - PubMed

MeSH terms